A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Administration, Intranasal
Angiotensin-Converting Enzyme 2
/ immunology
Animals
Antibodies, Bispecific
/ immunology
Antibodies, Monoclonal
/ chemistry
Antibodies, Neutralizing
Antibodies, Viral
/ immunology
COVID-19
/ immunology
Camelids, New World
Epitopes
/ chemistry
Female
Humans
Kinetics
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Neutralization Tests
Protein Binding
Protein Domains
Protein Engineering
/ methods
SARS-CoV-2
Serum Albumin, Human
/ chemistry
Single-Domain Antibodies
Spike Glycoprotein, Coronavirus
/ immunology
Delta
Nb15
Nb15-NbH-Nb15
SARS-CoV-2
VHH
bispecific
hACE2 mice
intranasal
nanobody
potent neutralizing
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
19 10 2021
19 10 2021
Historique:
received:
03
03
2021
revised:
08
07
2021
accepted:
29
09
2021
pubmed:
14
10
2021
medline:
16
11
2021
entrez:
13
10
2021
Statut:
ppublish
Résumé
The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19. Here, we characterize several receptor binding domain (RBD)-specific Nbs isolated from an Nb library derived from an alpaca immunized with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S); among them, three Nbs exhibit picomolar potency against SARS-CoV-2 live virus, pseudotyped viruses, and circulating SARS-CoV-2 variants. To improve their efficacy, various configurations of Nbs are engineered. Nb
Identifiants
pubmed: 34644535
pii: S2211-1247(21)01336-X
doi: 10.1016/j.celrep.2021.109869
pmc: PMC8492916
pii:
doi:
Substances chimiques
Antibodies, Bispecific
0
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Epitopes
0
Single-Domain Antibodies
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109869Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declared no competing interests. X.W. and Z.W. are listed as inventors on a China patent (CN202110120326.8) related with the Nbs for the treatment of SARS-CoV-2 infection.
Références
J Allergy Clin Immunol. 2001 Aug;108(2):250-7
pubmed: 11496242
Arthritis Res Ther. 2015 May 20;17:135
pubmed: 25994180
Virol Sin. 2018 Apr;33(2):201-204
pubmed: 29541941
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Pharmacol Ther. 2017 Jan;169:47-56
pubmed: 27373507
Viral Immunol. 2003;16(1):69-86
pubmed: 12725690
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Virol. 1987 Jun;61(6):1851-4
pubmed: 3553614
Sci Adv. 2021 May 26;7(22):
pubmed: 34039613
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Immunol Rev. 2015 Nov;268(1):340-64
pubmed: 26497532
Antib Ther. 2019 Mar 04;2(2):45-53
pubmed: 33928221
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20565-70
pubmed: 21059953
JCI Insight. 2020 Jul 9;5(13):
pubmed: 32641581
Otolaryngol Head Neck Surg. 2020 Oct;163(4):682-694
pubmed: 32660339
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Lancet Respir Med. 2021 Jan;9(1):21-32
pubmed: 33002427
BioDrugs. 2020 Feb;34(1):11-26
pubmed: 31686399
Nat Struct Mol Biol. 2020 Sep;27(9):846-854
pubmed: 32661423
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Mucosal Immunol. 2021 Mar;14(2):305-316
pubmed: 33244161
Science. 2020 Dec 18;370(6523):1479-1484
pubmed: 33154108
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Drug Discov Today. 2016 Jul;21(7):1076-113
pubmed: 27080147
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Immunity. 2020 Dec 15;53(6):1315-1330.e9
pubmed: 33275896
Antimicrob Agents Chemother. 2015 Oct 05;60(1):6-13
pubmed: 26438495
Nature. 2020 Jul;583(7818):830-833
pubmed: 32380511
Nat Commun. 2020 Sep 4;11(1):4420
pubmed: 32887876
Proc Natl Acad Sci U S A. 2021 May 11;118(19):
pubmed: 33893175
Emerg Microbes Infect. 2020 Dec;9(1):1034-1036
pubmed: 32403995
Cell Host Microbe. 2020 Jun 10;27(6):891-898.e5
pubmed: 32413276
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Science. 2020 Dec 18;370(6523):1473-1479
pubmed: 33154106